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The waiting list for kidney transplantation contin-
ued to grow between 1999 and 2008, from 41 177 to
76 089 candidates. However, active candidates repre-
sented the minority of this increase (36 951–50 624, a
37% change), while inactive candidates increased over
500% (4226–25 465). There were 5966 living donor (LD)
and 10 551 deceased donor (DD) kidney transplants
performed in 2008. The total number of pancreas trans-
plants peaked at 1484 in 2004 and has declined to 1273.
Although the number of LD transplants increased by
26% from 1999 to 2008, the total number peaked in
2004 at 6647 before declining 10% by 2008. The rate
of LD transplantation continues to vary significantly
as a function of demographic and geographic factors,
including waiting time for DD transplant. Posttrans-
plant survival remains excellent, and there appears to
be greater use of induction agents and reduced use
of corticosteroids in LD recipients. Significant changes
occurred in the pediatric population, with a dramatic
reduction in the use of LD organs after passage of the
Share 35 rule. Many strategies have been adopted to
reverse the decline in LD transplant rates for all age
groups, including expansion of kidney paired donation,
adoption of laparoscopic donor nephrectomy and use
of incompatible LD.
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Introduction
Despite a decade of efforts to increase access to kidney
transplantation, thousands of patients remain on waiting
lists around the United States. Among the most successful
strategies to reduce waiting time and improve posttrans-
plant outcome is the expansion of living donor (LD) trans-
plantation. The use of kidneys from LDs offers numerous
advantages, including reduced waiting times, improved op-
portunity for preemptive transplantation, shorter and less
expensive hospital stays and improved posttransplant out-
come (1–3). Unfortunately, there appears to be steady ero-
sion in the use of LD renal transplantation over the past 4
years, a development that threatens to increase morbidity
and mortality among patients with end-stage renal disease
(ESRD).
The first two sections of this article will review overall
trends in waiting list activity for kidney and pancreas trans-
plantation, as well as transplant rates and outcomes. These
data provide an important overview of the trends in wait-
ing times, donor demographics and expected survival fol-
lowing both deceased donor (DD) and LD kidney and DD
pancreas transplantation.
The remainder of the article focuses on the changing land-
scape of LD kidney transplantation. First, current trends
in donor and recipient characteristics are reviewed. Next,
the ongoing variation in the rates of LD transplant is
considered. Particular attention is paid to disparities as-
sociated with race, socioeconomic status and geogra-
phy. Posttransplant outcome and management is then as-
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Figure 1: Number of new and prevalent kidney waiting list
patients and deaths on the waiting list, 1999–2008.
immunosuppression strategies have influenced outcome.
The special case of LD pediatric kidney transplantation is
then considered in light of improved access to DD trans-
plantation resulting from the Share 35 policy, which prefer-
entially allocates DD kidneys from donors younger than 35
years to pediatric recipients. Finally, current strategies to
expand access to living donation are presented, including
paired donation (donor exchange) programs, increased use
of laparoscopic donor nephrectomy and increasing use of
ABO incompatible donors.
Unless otherwise noted, the statistics in the sections on
kidney and pancreas transplantation are drawn from the
reference tables of the 2009 OPTN/SRTR Annual Report.
Statistics for the third section about LD kidney transplan-
tation are drawn from both the reference tables and from
special analyses prepared by the SRTR. Additional infor-
mation about the methods of data collection and analy-
sis may be found in the data tables themselves and in
the Technical Notes of the Annual Report, both online at
http://www.ustransplant.org.
Kidney Transplantation
Kidney transplant waiting list trends
Over the past 10 years, the annual number of kidney-
alone transplants performed nationally grew by 27%, from
12 633 transplants in 1999 to 16 067 transplants in 2008
[Table 1.7]. During this period, the total number of candi-
dates listed for a kidney-alone transplant at any time dur-
ing the calendar year increased by 75%, from 57 058 to
99 750 [Table 5.3], while the total number of candidates
wait-listed at year-end for a kidney-alone transplant rose by
86%, from 43 632 to 80 972 [Table 1.3] (Figure 1). Growth
in the number of wait-listed patients has been accompa-
nied by a similar increase of 40% in deaths on the waiting
list, from 3318 in 1999 to 4638 in 2008 [Table 5.3]. How-
ever, while the absolute number of deaths has increased,
Figure 2: Waiting list death rates by diagnosis,∗ 1999–2008.
it is notable that the annual death rate for waiting list can-
didates has decreased, from 84 deaths per 1000 patient-
years at risk in 1999 to 63 deaths per 1000 patient-years
at risk in 2008 [Table 5.3]. During this period, the annual
death rate for waiting list candidates decreased by more
than 30% for adult and pediatric age groups. Among diag-
noses, there was more variation in the trend of death rates
over time. For candidates with diabetes and glomerular dis-
eases, the unadjusted waiting list mortality rate decreased
by 38% and 23%, respectively. For candidates with hyper-
tensive nephrosclerosis or tubular and interstitial diseases,
however, waiting list mortality rates decreased by 8% and
9%, respectively (Figure 2). While it is probable that these
trends reflect improvements in dialysis outcomes (4), they
may also reflect changes in transplant candidate selection
and preparation (see appendix H, table H.12 in Ref. 4).
Between December 31, 2002 and December 31, 2008,
the total number of candidates on the national kidney
transplant waiting list increased by 51% (Figure 3). How-
ever, not all of the components of the waiting list grew
Figure 3: Active/inactive status of kidney waiting list candi-
dates at year-end, 1999–2008.
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proportionally. While the number of active patients on the
waiting list rose by 14% [Table 5.1a], most of the recent
growth in the overall size of the waiting list reflects an in-
crease in the use of Status 7 (inactive status), as the num-
ber of inactive patients on the waiting list grew by 322%
[Table 5.1b]. Specifically, the number of active patients,
which was 36 951 on December 31, 1999, was 44 262 3
years later (a positive trend of 2437 per year), but 6 years
later in 2008 was 50 624 (a trend of 1060 per year). In
contrast, the number of inactive patients on the kidney
transplant waiting list increased slowly, from 4 226 candi-
dates at year-end in 1999 to 6 034 candidates in 2002 (a
trend of 603 per year). The number then more than quadru-
pled to 25 465 patients by December 31, 2008 (a trend of
3239 per year). This increase in the use of Status 7 has
been attributed to changes in OPTN policy in 2003 that al-
lowed wait-listed candidates to accrue waiting time during
the entire period that they are listed, whether active or in-
active (http://optn.transplant.hrsa.gov/PoliciesandBylaws2/
policies/pdfs/policy_7.pdf, see policy 3.5.11.1) (5). The rate
of increase in the number of active patients has declined
in recent years. From 1999 to 2003, there was a 23%
increase in active patients (corresponding to an average
increase of 5.3% per year). In 2004, there was a slight
decrease, and the yearly percentage increase afterwards
was 2%, 2%, 3% and 4% in 2008 (compared with 2007).
The proportion of candidates on the active kidney trans-
plant waiting list over the age of 50 years has increased
during the past decade, from 47% to 59% [Table 5.1a]
(Table 1). This shift in the age distribution of the waiting list
reflects changes in the rates of wait listing among the dif-
ferent age groups. New listings for candidates under age
50 increased 23%, from 11 482 to 14 173 during 1999–
2008, whereas the number of candidates aged 50 years
or older nearly doubled, from 9520 in 1999 to 18 878 in
2008 [Table 5.2]. The number of active candidates younger
than 50 years grew from 19 681 in 1999 to 21 248 in 2003
but remained between 20 340 and 20 772 over the next 5
years. The number of active candidates over age 50 rose
from 17 270 in 1999 to 24 227 in 2003, and then to 29 852
in 2008 [Table 5.1a]. In contrast, the number of inactive
candidates younger than 50 years increased from 2118 in
1999 to 3550 in 2003, and then to 9621 by 2008. The num-
ber of inactive candidates over 50 years grew dramatically,
from 2108 in 1999 to 4488 in 2003 and then to 15 844 in
2008 [Table 5.1b]. As shown in Table 1, the percentage of
candidates by age group on the waiting list in either active
or inactive status is roughly proportional to their represen-
tation on the total waiting list.
The distribution of race among candidates active on the
kidney waiting list has also changed over the past 10 years
(Table 1). The number of white and African American ac-
tive candidates grew from 15 784 and 13 486, respectively,
in 1999 to 19 243 and 17 091 in 2008 [Table 5.1a]. At the
same time, however, the percentage of white candidates
on the active waiting list declined, from 43% to 38%, and
Table 1: Annual number and distribution of kidney waiting list
patients by patient characteristic and status at year-end, 1999–
2008
Active Inactive
Characteristic 1999 2004 2008 1999 2004 2008
N 36 951 45 290 50 624 4226 11 851 25 465
<35 years 18% 15% 12% 16% 13% 11%
35–49 years 35% 31% 29% 34% 30% 27%
50–64 years 37% 41% 42% 37% 42% 44%
65+ years 10% 14% 17% 12% 16% 18%
White 43% 39% 38% 46% 40% 39%
African
American
36% 35% 34% 38% 39% 38%
Hispanic/Latino 13% 17% 18% 10% 15% 17%
Asian 6% 8% 8% 4% 5% 5%
Other/multirace 1% 1% 1% 2% 1% 1%
Glomerular
diseases
24% 22% 21% 23% 20% 18%




18% 20% 23% 14% 19% 22%
Other 35% 31% 29% 38% 34% 29%
Source: Tables 5.1a, b and SRTR analysis, November 2009.
the percentage of African American candidates decreased
slightly, from 36% to 34%. The total number of active His-
panic/Latino candidates nearly doubled, from 4870 in 1999
to 9314 in 2008; Asian candidates also increased over the
same time, from 2385 to 4265 [Table 5.1a]. These changes
are reflected by a proportionate increase in the percentage
representation of Hispanic/Latino and Asian candidates in
both active and inactive status on the waiting list.
The pattern of diagnoses (glomerular diseases, hyperten-
sive nephrosclerosis, diabetes and other diseases) of can-
didates on the active kidney waiting list has also evolved
over the past 10 years (Table 1). Overall, the percentage
of active candidates with diabetes and hypertension has
increased, from 23% to 28% and from 18% to 23%, re-
spectively, whereas the percentage with glomerular dis-
ease has declined, from 24% to 21%. In 2008, the dis-
tribution of diagnoses was roughly proportional between
active and inactive candidates on the waiting list and may
reflect changes in the overall demographic characteristics
of the list (age, race, sex) [Tables 5.1a and 5.1b]. Thus, it
does not appear that the use of Status 7 is disproportion-
ately associated with any specific demographic or diagnos-
tic characteristics.
Among new candidates listed between 1999 and 2005,
there has been relatively little change in the median time
to receive any kidney transplant, that is, from either a DD
or LD. In 1999, the median time to any kidney transplant
was 1127 days; in 2005 (the most recent year for which
this calculation is possible), the median time to any kidney
transplant was 1269 days [Table 5.2].
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Figure 4: SCD, ECD and DCD kidney transplants, 1999–2008.
Kidney transplant trends
The annual number of DD kidney transplants, including
multiorgan transplants but excluding simultaneous pan-
creas kidney (SPK) transplants, rose from 8043 in 1999
to a peak of 10 659 in 2006, and then fell to 10 551 trans-
plants in 2008 [Table 5.4]. Non-SPK multiorgan transplants
increased by 80%, from 255 in 2002 to 460 in 2008 [Table
1.8]. In 2008, kidney-liver (379) and kidney-heart (66) made
up 97% (99%, if kidney-liver-other and kidney-heart-other
are included) of these transplants.
The number of standard criteria donor (SCD) transplants,
expanded criteria donor (ECD) transplants and non-ECD
transplanted kidneys recovered through donation after car-
diac death (DCD) grew by 12%, 55% and 794%, respec-
tively, between 1999 and 2008 [Table 5.4] (Figure 4).
In these analyses, the ECD definition includes DCD kid-
neys that meet the OPTN ECD criteria. In 2008, there were
7503 SCD, 1912 ECD (120 of which were ECD/DCD) and
1136 DCD kidney transplants performed. The greatest nu-
merical increment compared with 2002 has been in DCD
transplants, with a gain of 872. SCD increased by 513,
and ECD (includes ECD/DCD) by 627 [Table 5.4]. There
were 37 fewer total transplants in 2008 (10 551) than in
2007 (10 588); this change represented 227 fewer SCD,
83 more ECD (includes ECD/DCD) and 107 more DCD
transplants [Table 5.4]. Although the percentage of SCD
kidneys allocated to candidates younger than 50 years has
declined, from 58% in 1999 to 46% in 2008 [Table 5.4a],
these younger candidates continued to receive SCD kid-
neys at a higher rate than their proportion on the waiting
list, which was 53% in 1999 and 40% in 2008 [Table 5.1a,
5.1b].
The 24% growth in DD kidney transplantation since 2002
appears to be largely driven by the increase in conversion
rates [Table 5.4] (Figure 5). This rate is defined as the num-
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HRSA Collaboratives began in April 2003 
Figure 5: Average conversion and discard rates for all OPOs,
2002–2008.
by the number of eligible deaths defined as any ventilated
death reported by a hospital that is evaluated and that
meets organ donor eligibility requirements. Nationally, the
average conversion rate grew from 48% in 2002 to 67%
in 2008 (Figure 5). However, there was also an increase
in the discard rate, from 13% in 2002 to 17% in 2008.
Conversion rates may have been affected by the efforts of
the Health Resources and Services Administration (HRSA)
Transplant Growth and Management collaboratives, which
began in 2003. The HRSA transplant collaborative has fo-
cused attention on successful strategies to improve con-
version rates to reach a goal of 75%.
Kidney transplant patient and graft survival trends
At the end of 2007, 144 805 patients had a functioning kid-
ney transplant compared with 83 545 in 1999, an increase
of 73% [Table 5.16]. These numbers represent a substan-
tial increase over those reported in prior Annual Reports,
given that they are based on calculations that more com-
pletely incorporate data from the Centers for Medicare and
Medicaid Services (CMS) on ESRD patients. For single kid-
ney transplants (multiorgan and SPK transplants excluded)
performed prior to 2008, 1-, 5- and 10-year patient sur-
vival was best for recipients of LD kidneys, intermediate
for non-ECD DD recipients, and lowest for those receiving
ECD kidneys (Figure 6). Unadjusted patient survival rates
at 5 years were 91% for recipients of LD kidneys, 84% for
non-ECD DD kidneys and 72% for ECD kidney transplants.
Kidney graft survival followed the same pattern as that
seen for recipient survival (Figure 7). Graft survival was
best for recipients of LD kidneys, intermediate for non-
ECD transplants and lowest for ECD transplants. At 5
years, the unadjusted graft survival rate was 81% for LD,
72% for non-ECD and 57% for ECD transplants. Each year
since 2002, the adjusted and unadjusted first-year graft sur-
vival has either improved or remained the same for ECD
and non-ECD kidney transplants. For LD transplants, this
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Source: 2009 OPTN/SRTR Annual Report, Tables 5.14a, b, d.
Figure 6: Unadjusted 1-year (2006–2007), 5-year (2002–2007)
and 10-year (1997–2007) kidney recipient survival, by donor
type.
has been true as well, except for the 2003–2004 drop of
0.2–0.3% [Tables 5.9 a, b, d and 5.11 a, b, d]. The 1-year
unadjusted graft survival in 2007 compared with 2002 was
97% versus 95% for LD, 93% versus 91% for non-ECD,
and 86% versus 80% for ECD transplants [Tables 5.9 a, b,
d and 5.11 a, b, d]. These differences were all statistically
significant, with p < 0.0001.
Regional differences in waiting times
Once an ESRD patient is listed, access to a kidney trans-
plant is dependent upon several factors, including blood
type, HLA, age (pediatric vs. adult) and willingness to ac-
cept an ECD kidney. One important factor in determining
waiting times is the donation service area (DSA), as illus-
trated in Figure 8. This figure displays the DSAs according
to the median waiting time, that is, the number of months
it took for half of the candidates listed from July 1, 2002 to
December 31, 2007 to receive transplants. In five DSAs,
fewer than half of the candidates during this period had
received transplants as of June 30, 2008; these DSAs re-
ceived the darkest shading on the map. Different DSAs can
have very different waiting times: a quarter of the DSAs had
100%)



































Source: 2009 OPTN/SRTR Annual Report, Tables 5.10a, b, d.
*Death is included as an event.
Figure 7: Unadjusted 1-year (2006–2007), 5-year (2002–2007)
and 10-year (1997–2007) kidney graft survival,∗ by donor type.
median waiting times shorter than 19 months and a quarter
had median waiting times longer than 37 months.
Pancreas Transplantion
Pancreas transplant waiting list trends
The number of pancreata recovered peaked at 2045 in
2005, fell slightly in 2006 to 2032 and fell further in 2008 to
1831 [Table 1.1]. At the end of 2008, there were 3765 peo-
ple waiting for a solid organ pancreas transplant: 2310 for
an SPK, 870 for a pancreas after kidney (PAK) and 585 for a
pancreas transplant alone (PTA). This was a 41% increase
over the total number in 1999, indicating a growing dis-
crepancy between the number of candidates wait-listed for
pancreas transplantation and organs available [Table 1.3].
More recently, the PTA and SPK waiting list populations
have remained almost constant, with the 2008 counts dif-
fering from the 2007 counts by one and three patients,
respectively. PAK counts decreased from 933 to 870 in
2007 and 2008 [Table 1.3].
The downward trend in new registrations for SPK or PAK
continued in 2008 (Figure 9). The total number of new
pancreas waiting list registrations grew from 2329 in 1999
to a high of 2796 in 2000, but fell to 2349 by 2008. New PAK
waiting list registrations rose from 307 in 1999 to a high of
624 in 2004, falling to 334 in 2008. New SPK registrations
rose from 1804 in 1999 to a high of 2007 in 2000, and
then declined to 1603 in 2008. PTA registrations showed
continued growth between 1999 and 2008, from 218 to
412 [Table 1.5].
Median waiting times decreased in 2007 for SPK and PTA
transplants, from 444 to 406 days and from 436 to 260
days, respectively. The median waiting time for PAK has
increased, from 219 days in 1999 to 887 days in 2006,
with data not available yet for 2007 [Table 1.5].
Pancreas transplant trends
The overall number of pancreas transplants rose from 1300
in 1999, peaked at 1484 in 2004 and has since declined to
1273 (Figure 10). The number of SPK transplants remained
between 871 and 941 from 1999 to 2006, dropping to 836
in 2008; the number of PAK transplants peaked at 420 in
2004, dropping to 214 in 2008. The cause of this decrease
in pancreas transplant numbers is uncertain but has been
attributed to several factors, including OPTN rules that pro-
hibit the use of kidneys for SPK transplants in DSAs that
owe a high number of kidneys to other regions under the
payback system. Other factors include an uneven distri-
bution of pancreas transplant programs across the United
States, caution by many transplant programs in the accep-
tance of pancreata recovered outside their own DSA, and
age and obesity trends in the donor population (6,7). The
preponderance of pancreas transplants are SPK, account-
ing for 66% of all pancreas transplants in 2008.
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Figure 8: Unadjusted median time
to transplant by OPO (listed from
July 1, 2002–December 31, 2007) for
kidney.
Pancreas transplant patient and graft survival trends
Despite trends toward fewer pancreas transplants and
waiting list registrations, the total number of patients alive
with a functioning pancreas graft increased 60%, from
6031 in 1999 to 9678 in 2007 (Figure 11). The largest rel-
ative increases over the past 9 years occurred in the PAK
and PTA populations, both of which grew roughly 3-fold.
Nonetheless, SPK recipients represent by far the largest
cohort of patients alive with a functioning pancreas graft.
Patient survival rates were similar for SPK, PAK and PTA
recipients at 1 year (ranging from 96% to 98%) and 3 years
(roughly 92%) (Figure 12). The 5- and 10-year unadjusted
patient survival rates were statistically (p ≤ 0.07) lowest
for PAK recipients at 85% and 68%, respectively, and
higher for SPK (87% and 71%, respectively) and PTA re-
cipients (89% and 76%, respectively) [Table 1.13]. Among
pancreas recipients, those with SPK transplants experi-
enced the best unadjusted pancreas graft survival rates:
Figure 9: New registrations on pancreas waiting list, by trans-
plant type, 1999–2008.
85% at 1 year (p = 0.01) and 55% at 10 years (p < 0.001)
(Figure 13). Graft survival rates for PAK and PTA recipients
were lower than for SPK recipients, with 1-year rates of
80% and 76%, respectively, and 10-year rates of 37% and
35%, respectively [Table 1.13].
LD Kidney Transplantation: Challenges
and Opportunities
LD trends
There were 5966 LD kidney transplants in 2008 [Table
5.4d]. This represents a 26% increase in the number
of LD transplants compared with 1999. Trends in living-
related and living-unrelated kidney donors are shown in
Figure 14. The number of living-related kidney donors
grew from 3629 in 1999 to 4352 in 2001, where it re-
mained roughly constant until 2004 at 4341. Since then,
the number of living-related donors has decreased, falling
Figure 10: Pancreas transplants, by transplant type, 1999–
2008.
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Source: 2009 OPTN/SRTR Annual Report, Tables 6.16, 7.16, 8.16.
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Figure 11: Number of recipients living with a functioning pan-
creas transplant at end of year, 1999–2007.
to 3498 in 2008. From 1999 to 2006, the number of living-
unrelated kidney donors grew steadily, from 1053 to 2350.
Between 2004 and 2008, the number of living-unrelated
kidney donors remained between 2195 and 2350 (Figure
14). The cause of decline in LDs is unclear but may re-
flect several factors: an aging recipient population with a
more limited number of potential donors; a declining em-
phasis on recruitment of LDs; changes in economic fac-
tors leading to increased reluctance to donate and the
impact of improved access to DD kidneys for pediatric
patients.
The mean age of the LD among adult recipients has shown
a steady increase, from 39.6 years in 1999 to 41.4 years in
2008 (Figure 15). Since 2005, living donation decreased for
adult donors below 50 years but increased for adult donors
over age 50 [Table 2.9]. There were 89 donors (1.5% of all
LDs) age 65 and over in 2008. In spite of the relative in-
crease in the mean age of the LD, the trend of the mean
preoperative renal function in this group has remained rela-
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Figure 12: Unadjusted 1-year, 3-year, 5-year and 10-year pan-
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Source: 2009 OPTN/SRTR Annual Report, Table 1.13.
*Death is included as an event.
Figure 13: Unadjusted 1-year, 3-year, 5-year and 10-year pan-
creas graft survival,∗ by transplant type.
0.88 and 0.92 mg/dL from 1999 to 2008 among LDs who
donated to adult recipients) (Figure 16).
From 1999 to 2007, the pattern of living donation for men
and women was similar. But in 2008, female LDs increased
by 112, from 3506 the previous year to 3618, while male
LDs decreased by 188, down to 2350 [Table 2.9]. The
numbers of Hispanic/Latino and Asian LDs in 2008, 820
and 237, respectively, were very similar to those in 2004
[Table 2.9]. LD transplants decreased from 2004 to 2008
in both whites (4593 to 4126) and African Americans (937
to 717) [Table 2.9].
Use of LD kidneys for retransplantation after failed re-
nal transplant: The total number of repeat kidney trans-
plants increased steadily, from 1559 in 1999 to 2103 in
2006, and then declined to 1851 in 2008. Overall, the
number of patients retransplanted using an LD (regard-
less of the source of the original organ) increased from
429 in 1999 to 714 in 2005, then declined to 612 in 2008
(Figure 17, Table 2). In 2008, regardless of the source
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Source: 2009 OPTN/SRTR Annual Report, Table 5.4d
Figure 14: Trends in living related and living unrelated donors,
1999–2008.
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Source: SRTR Analysis, July 2009
Figure 15: Trends in LD age, 1999–2008.
retransplanted using a DD rather than an LD. Patients with
a prior DD transplant were less likely to be retransplanted
with an LD organ (22%) compared with patients with a
prior LD who received a second LD (46%).
LD after extra-renal transplantation: From 1999 to
2008, there were 3318 kidney transplants following extra-
renal transplantation (lung, liver or heart); 1555 were from
LDs and 1763 from DDs (Table 3). Annual use of LD trans-
plants following extra-renal transplants increased from 86
to 194 between 1999 and 2003 and thereafter declined to
146 in 2008. DD kidney transplants in recipients of prior
lung, liver or heart transplants followed a similar pattern,
increasing from 115 in 1999 to a peak of 240 in 2006 and
then declining to 227 in 2008.
Variation and disparity in access to LD transplantation
Despite the clear survival benefits of LD transplantation,
there are significant, ongoing disparities in access to LD
organs that may exacerbate the declining rates of trans-
plantation noted above. Analyses of trends in the rate of
transplant during the past decades reveal substantial varia-
tion among potential recipients based on age, sex and race.

























































Source: SRTR Analysis, July 2009
Figure 16: Trends in living donor creatinine, 1999–2008.
Figure 17: Trends in LD retransplantation, 1999–2008.
across geographic regions, potentially as a function of wait-
ing time and demographic differences.
Demographic and clinical factors associated with LD
access: Among candidates waiting for transplant, the
youngest children are the most likely to receive an LD
transplant; however, the percentage declines among older
children (Figure 18). This trend abruptly reverses at age
18, when pediatric priority is no longer in effect. Younger
adults without access to the pediatric list are much more
likely than older recipients to receive an LD transplant.
The propensity to undergo LD transplant then steadily de-
creases beyond age 35.
Members of racial and ethnic minorities who receive
transplants continue to be significantly less likely to
have received an LD transplant even after adjustment for
demographic factors, insurance and socioeconomic sta-
tus. Among patients who received a transplant, African-
American recipients are less than half as likely to have
received an LD transplant as white patients (odds ra-
tio [OR] 0.42 95%; confidence interval [CI] [0.40, 0.44]).
Hispanic/Latino candidates (OR 0.82 [0.75, 0.89]) and
Table 2: Total number of repeat kidney transplants, 1999–2008
Year of DD- DD- LD- LD- unk- unk- Total Re-tx Total
Re-Tx DD LD DD LD DD LD with LD Re-tx
1999 650 156 191 125 289 148 429 1559
2000 692 192 251 179 300 137 508 1751
2001 665 240 237 233 279 170 643 1824
2002 702 257 263 270 223 133 660 1848
2003 708 291 266 312 167 110 713 1854
2004 810 276 343 309 185 106 691 2029
2005 815 298 360 324 131 92 714 2020
2006 870 269 439 345 113 67 681 2103
2007 826 215 389 322 101 68 605 1921
2008 755 215 400 344 84 53 612 1851
Source: SRTR Analysis, August 2009.
Re-Tx = repeat transplant; DD = deceased donor kidney; LD =
living donor kidney; and unk = unknown.
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Table 3: Number of kidney transplants, including living donor, fol-












Year of Total Total
transplant LD DD LD DD LD DD Total
1999 49 82 37 33 86 115 201
2000 75 101 34 37 109 138 247
2001 90 111 50 44 140 155 295
2002 108 94 60 44 168 138 306
2003 133 96 61 45 194 141 335
2004 135 120 58 58 193 178 371
2005 125 170 61 54 186 224 410
2006 114 177 54 63 168 240 408
2007 112 144 53 63 165 207 372
2008 114 167 32 60 146 227 373
Total 1055 1262 500 501 1555 1763 3318
Source: SRTR Analysis, August 2009.
LD = living donor.
candidates of ’other’ racial classifications are similarly dis-
advantaged (OR 0.53 [0.50, 0.56]). Despite near universal
coverage for patients with ESRD, type of insurance also
has a significant effect on access to LD transplantation.
Patients with private health insurance were nearly three
times more likely to receive an LD kidney compared with
those with Medicare only (OR 2.74 [2.61, 2.88]). However,
the difference was smaller for candidates with Medicaid
compared with Medicare (OR 1.09 [1.01, 1.16]). Higher
educational achievement was also associated with an in-
creased rate of LD transplant (OR 1.28 [1.24, 1.33]) for
patients with at least some college education.
A variety of clinical factors that affect the use of LD
transplantation were analyzed in a multivariate model. Af-
ter adjusting for demographic and socioeconomic status,
patients with a body mass index greater than 35 (OR
60%
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Percentages adjusted through random effects model using DSA/blood type
Source: SRTR Analysis, July 2009
Figure 18: Percentage of living donor kidney-alone transplant
by recipient age, 1999–2008 data.
0.92 [0.88, 0.97] vs. 25–30), panel reactive antibody (PRA)
greater than or equal to 80% (OR 0.45 [0.42, 0.50]) and
male sex (OR 0.83 [0.81, 0.86]) were all less likely to
receive an LD kidney. Interestingly, compared with pa-
tients with glomerulonephritis, candidates with diabetes
were significantly more likely to undergo LD transplant
(OR 1.35 [(1.28, 1.44]), as were candidates with hyper-
tension (OR 1.16 [1.10, 1.22]), polycystic kidney disease
(OR 1.24 [1.17, 1.32]) or other and/or missing causes of
renal failure (OR 1.79 [1.63, 1.96]). A prior history of ma-
lignancy also increased the chance of receiving an LD
transplant (OR 1.14 [1.06, 1.21] (SRTR analysis, August
2008).
Geographic variation in LD use and access: LD use
varies markedly by geography. Using DSA coverage ar-
eas, LD transplant rates were compared with the under-
lying population of patients with ESRD (Figure 19). The
mean ratio of LD recipients per 100 incident ESRD pa-
tients under the age of 75 during 1999–2007 was 8.2, with
an interquartile range of 4.9–10.5. The DSA with cover-
age in Minnesota, South Dakota, North Dakota and parts
of Wisconsin had the highest rate of LD transplant at
32.98 of ESRD patients, while the DSA with coverage in
Mississippi had the lowest at 0.15 (Figure 19). After adjust-
ing for differences in the underlying population demograph-
ics to the national mean for age, race, sex and diabetes,
the ratio of LD recipients per 100 incident ESRD patients
still varied from 0.17 to 26.57.
Effect of DD waiting time on the use of LD transplant:
Among the factors that influence the use of LD kidneys
is the waiting time within the region. As the waiting time
within a given OPO increases, it appears that use of LD
organs increases proportionately (Figure 20).
To determine the effect of waiting time on LD rates, use of
LD transplantation was examined in each OPO for each
blood group over the period 1999–2008. This analysis
included 123 127 transplants, of which 49% were LD. Re-
cipients of multiorgan transplants and those transplanted
with nonlocal organs were excluded. Assessments of the
effect of waiting time were adjusted for recipient demo-
graphic and clinical factors.
Overall, the odds of receiving an LD transplant compared
with a DD transplant increased by 48% for each additional
year of waiting (OR 1.48 [1.36, 1.60]) after adjustment for
other donor and recipient covariates. This effect appears to
have diminished over the past several years from a peak
in 2001, although the relationship in 2008 is still highly sig-
nificant (OR 1.31 [1.20, 1.44]). While the relationship be-
tween waiting time and the percentage of LD transplants
varied by patient demographic, it was still positive for all
adult groups. Pediatric recipients tended to have higher
percentages of transplants than other age groups; these
percentages tended not to be affected by the length of
waiting times in their DSAs.
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Figure 19: Living donor transplants/
ESRD population, 1999–2008.
Trends in posttransplant outcomes among LD kidney
recipients
Recipient characteristics and outcomes: Graft survival
for LD kidney transplant recipients was at or above 95%
through 1 year for all age groups over 1 year of age. In-
terestingly, by 5 years, LD kidney transplant graft survival,
adjusted for the average 1-year cohort demographics, dips
below 80% for individuals who were adolescents or young
adults at time of transplant (age 12–17 years, 76%; age
18–34 years, 79%), as well as for individuals over age 65
at transplant (74%). At 10 years posttransplant, fewer than
two-thirds of grafts were functioning within all age groups,
save for individuals who were transplanted at age 5 or
younger [Table 5.8d].
African-American LD transplant recipients had lower rates
of unadjusted and adjusted graft survival at 5- and 10-years
(adjusted graft survival at 5 years, 73%; 10 years, 45%)
Figure 20: DSA/ABO median wait time versus percentage liv-
ing donor transplantation, 1999–2008.
compared with other races and ethnicities. There were
no major differences in unadjusted or adjusted graft sur-
vival between male and female recipients, or in unadjusted
graft survival rates across blood types. First-time transplant
recipients had statistically significantly better unadjusted
graft survival at 5 years (82% vs. 78%, p < 0.001) and at
10 years (60% vs. 55%, p < 0.001) [Tables 5.8d, 5.10d].
While nearly all LD kidney transplant diagnosis groups had
relatively similar rates of graft survival through 3 months,
1 year and 5 years, individuals who had diabetes or renovas-
cular or other vascular diseases as the primary diagnoses
for kidney failure were more likely to have failed grafts at
10 years (adjusted graft survival diabetes, 48%; renovas-
cular and other, 49%) [Table 5.8d].
Transplant-related variables and trends over time: The
need for dialysis within the first week after an LD trans-
plant (4% of kidney-alone transplants in 2006–2007) was
associated with a marked reduction in graft survival at ev-
ery time point compared with individuals who did not need
dialysis early after LD transplant [Table 5.10d].
Outcomes were generally similar above an annual center
volume of 47 transplants per year. However, facilities with
29–47 transplants per year had statistically significant re-
ductions in graft survival compared with facilities with more
than 47 transplants per year (p-values ranging from 0.003
to 0.07 by 3-month–10-year time period, and by size: 48–81
or 82+ transplants). The range of 10-year adjusted graft sur-
vival across all states with at least 100 LD recipients from
1997 to 2007 was 39%–77%, with the majority of states
reporting survival of 55%–65% at 10 years [Table 5.8d].
Donor age over 65 years was associated with a marked re-
duction in 5- and 10-year unadjusted graft survival (5 years,
61%; 10 years, 29%) [Table 5.10d].
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Between 1999 and 2007, unadjusted graft survival in-
creased from 95% to 97% at 1 year. Three- and 5-year sur-
vival rates also improved since 1999, but the improvement
in 5-year graft survival between 1999 and 2003 was not
statistically significant. By 2005, the latest year for which
3-year posttransplant survival is available, 3-year graft sur-
vival had improved to 89%, compared with 88% in 1999.
By 2003, 5-year graft survival had improved to 81%, com-
pared with 80% in 1999 [Table 5.11d].
Adjusted patient survival following LD kidney transplant for
all age groups was at or above survival for those 65 years
and older: 99% at 3 months and 97% at 1 year [Table
5.12d]. At 5 years after transplant, recipients between the
ages of 1–49 years at transplant had at least 93% survival;
recipients ages 50–64 years decreased to 89% survival
and those 65 years and older had even lower survival at
79%. Similar trends were found at 10 years [Table 5.12d].
African-American recipients had slightly lower adjusted
10-year patient survival rates than whites (73% vs. 77%),
while Hispanic/Latinos experienced better survival (83%)
than both groups (p < 0.001 for all groups) [Table 5.12d].
There were no statistically significant differences in ad-
justed LD patient survival when comparing males and fe-
males. There were also no differences comparing individ-
uals with different blood types at 3 months and 1 year;
however, type A recipients had significantly lower unad-
justed survival than type O recipients at 5 years (90% vs.
92%) and 10 years (76% vs.78%) [Table 5.14d].
Having renal disease related to diabetes or neoplasm was
associated with reduced adjusted patient survival at 5
years in contrast with the other disease categories; this
was statistically significant for diabetes. By 10 years, indi-
viduals with diabetes as a primary cause of kidney failure
had only 58% unadjusted patient survival after an LD trans-
plant. This was even lower than that for individuals who had
renovascular and other vascular diseases (70% 10-year un-
adjusted survival) or neoplasms (71% 10-year unadjusted
survival) as primary causes of kidney failure [Table 5.14d].
The need for dialysis within the first week following an LD
transplant was associated with reduced patient survival. At
5 years after an LD transplant, unadjusted patient survival
was 79% versus 92% for those not in need of dialysis;
this difference persisted at 10 years (62% vs. 78%) [Ta-
ble 5.14d]. We report these figures with the caveat that
dialysis within the first week captures both delayed graft
function and primary nonfunction.
There were no marked differences in outcomes in unad-
justed patient survival when categorized by center vol-
umes, with the exception of the smallest centers (0–12
per year) with statistically significant better survival at 5-
and 10-years [Table 5.14d]. In evaluating unadjusted pa-
tient survival in states that had more than 100 recipients
reported, the range of 5-year patient survival was 88–97%.
The range for 10-year unadjusted patient survival was 66–
Figure 21: Trends in recipient steroids, maintenance and in-
duction therapy, 1999–2008.
87%. There appeared to be a modest effect, albeit not
statistically significant, in reduced unadjusted patient sur-
vival for individuals with PRA levels at 80% or greater at
5 years after an LD transplant. However, survival for this
group was higher (although, again, not reaching statistical
significance) at 10 years than for recipients with 0–9% or
10–79% PRA levels [Table 5.14d].
As with graft survival, donor age ≥65 years was associated
with a marked difference in patient survival at 10 years
following LD transplant in contrast to all younger categories
of donor age (unadjusted 10-year survival, 46%; all of the
other age categories, ≥74%) [Table 5.14d].
Immunosuppression in the LD recipient: Immunosup-
pression management of the LD kidney recipient has
changed dramatically over the past decade (Figure 21). The
use of any induction regimen has increased between 1999
and 2008, from 42% of transplants to 81%. The most
frequently used agents in 1999 were IL-2 receptor antago-
nists, which were used in 31% of patients overall. In 2008,
41% of patients received rabbit antithymocyte globulin
(Thymoglobulin), 30% received an IL-2 receptor antagonist
and 12% were treated with alemtuzumab (Campath).
Maintenance immunosuppression regimens have also
evolved in the LD transplant recipient. In 1999, 96%
of recipients were discharged with steroids; 31% were
on tacrolimus and 63% were on a cyclosporine prepa-
ration. By 2008, only 59% of patients were discharged
on steroids, while 86% were on tacrolimus and 8% on
cyclosporine. The use of maintenance steroids following
transplant has also decreased over time. In 1999, 83%
of LD recipients remained on triple therapy at 1 year af-
ter transplant (calcineurnin inhibitors [CNI], antimetabolyte,
corticosteroids) compared with only 55% in 2008. The
most common regimen for patients on dual therapy
in 2008 was tacrolimus/mycophenolate mofetil (32% of
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Table 4: Comparison of pediatric kidney transplants pre- and post-Share 35 by donor type and recipient age
Recipient age (years)
0–5 6–10 11–18 Pediatric total
Policy period Donor type N % N % N % N %
Pre-Share 35 9/28/02 through 9/27/2005 Deceased 154 33.3 195 46.2 744 58.1 1093 46.5
Living 309 66.7 227 53.8 720 41.9 1256 53.5
All 463 100.0 422 100.0 1464 100.0 2349 100.0
Post-Share 35 9/28/05 through 9/27/08 Deceased 214 46.9 261 62.3 1077 67.5 1552 62.8
Living 242 53.1 158 37.7 519 32.5 919 37.2
All 456 100.0 419 100.0 1596 100.0 2471 100.0
Source: Organ Procurement and Transplantation Network. OPTN/UNOS Pediatric Transplantation Committee Descriptive Data Request.
Final: Evaluation of modification to OPTN/UNOS policy on pediatric priority for kidneys from deceased donors under age 35. March 26,
2009.
recipients). Only 2% of patients were on tacrolimus
monotherapy (SRTR analyses, data as of July 2009).
Decrease in living donation among pediatric
transplants after share 35
Since September 28, 2005, under the Share 35
allocation policy (http://optn.transplant.hrsa.gov/
PoliciesandBylaws2/policies/pdfs/policy_7.pdf), children
listed for kidney transplant before the age of 18 years have
received first priority for kidneys from DDs younger than
35 years, when the kidneys are not shared mandatorily for
the following reasons: 0 HLA mismatching, renal/nonrenal
organ allocation, locally for prior living organ donors or
for candidates 18 years or older with PRA levels 80%
or greater. In the first 3 years after Share 35 (post-Share
35), the total number of kidney transplants for children
increased, primarily in the 11–18 year age group, and
the total number of DD transplants increased in every
pediatric age group, compared with the 3-year period just
prior (pre-Share 35) (Table 4). There was a corresponding
substantial decrease in the number of LD transplants for
children in all age groups. The decrease in LD transplants
reflects a general downward trend for all LD transplants
since 2004, but for children post-Share 35, the 24%
decrease was out of proportion to the smaller 18% and
16% decreases for adults aged 18–34 and 35–49 years,
respectively, during the same time period (Figure 22).
Parent-to-child donation, the most common type of LD
transplant for children, decreased from 899 (72% of LD
transplants) to 623 (68%) after Share 35 (8).
The reasons for the decline in pediatric LD kidney trans-
plants after Share 35 are unclear. The demographic charac-
teristics for pediatric LD accepted and completing donation
post-Share 35 have not been different from pre-Share 35,
so selection criteria do not seem to be more stringent (8).
However, no data exist to evaluate the general health of
the LD pool and whether factors such as obesity, diabetes
and hypertension—which have increased in prevalence in
the adult population in the last decade—have adversely af-
fected the LD rate, causing more potential donors to be
screened out. It is likely that a shorter waiting time and
greater availability of DD kidneys for pediatric patients af-
ter Share 35 may be influencing parents and candidates to
wait for a DD kidney rather than putting family members
or friends through the LD process; parents and candidates
may be saving an LD kidney for a future repeat kidney
transplant when needed.
With more pediatric patients, especially adolescents, re-
ceiving DD kidney transplants that are poorly matched
immunologically—more than 5–6 antigen mismatches and
2 DR mismatches (8)—compared with living related donor
kidneys, concern arises about long-term consequences,
such as decreased graft survival and patient sensitiza-
tion for future transplant. The short follow-up time since
implementation of Share 35 in 2005 does not allow for
this concern to be fully addressed. At 2 years of follow-
up, no significant difference has been observed in inci-
dence of delayed graft function, 6- or 12-month acute re-
jection rates, or median serum creatinine at 12 months (8).
Short-term graft survival for all pediatric kidney transplants,
regardless of donor type, is no different for pre- and post-
Share 35. Early analysis suggests post-Share 35 LD kidney
transplants may demonstrate improved graft survival com-
pared with post-Share 35 DD, pre-Share 35 LD and pre-
Share 35 DD transplants (Figure 23). Long-term follow-up
Figure 22: Living donor recipient age by year of transplant,
1999–2008.
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Source: SRTR Analysis, July 2008
Figure 23: Graft survival for pediatric kidney transplants by
donor type performed in the 2 years pre- or post-Share 35.
is needed before a difference in graft survival can really be
demonstrated.
Strategies to increase living kidney donation
Despite the outstanding outcomes associated with LD
kidney transplantation, medical and logistical barriers to
living donation still exist. Over the last decade, efforts
have been made to increase the feasibility of live dona-
tion for healthy, willing donors through a number of dif-
ferent modalities. These include the growth of programs
for transplantation across immunological or blood group
incompatibilities, the development of kidney paired dona-
tion (KPD) programs, wider dissemination of laparoscopic
donor nephrectomy to reduce donor recovery time, and a
national program to defray the costs associated with live
donation.
Incompatible kidney transplantation: Estimates sug-
gest that hundreds of candidates each year are rele-
gated to the DD waiting list because of blood type or
HLA incompatibilities with their healthy, willing, intended
live donors (9). Options for these patients include KPD
(10,11), ABO incompatible (ABOi) transplantation (12–
15) and LD positive-crossmatch (posXM) desensitization
(16,17).
The original paradigm of KPD, where two or more incom-
patible pairs exchange donors such that compatible trans-
plants result (18), has been expanded to include the use of
compatible pairs (19) and nondirected donors (20,21). Geo-
graphic barriers have also been overcome by mathematical
optimization (11) and by replacing donor travel with organ
transport (22,23). As a result, according to LD relationships
reported to the OPTN, the use of KPD has doubled each
year since 2005 (Figure 24).
Growth has also been seen in ABOi and posXM programs.
The increasing numbers of ABOi transplants, as well as
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Source: SRTR Analysis, July 2009
Figure 24: Trends in paired donation, 2000–2008.
are shown in Table 5. Although the use of desensitization
is not reported to the OPTN, some inferences regarding
growth of posXM transplantation can be made by studying
the number of highly sensitized recipients (PRA ≥ 80%)
transplanted each year, particularly those with non-HLA-
identical donors (Table 5).
The increase in ABOi and posXM transplants can also be
seen in terms of center-level clustering. In other words,
an increase in the number of incompatible transplants
performed can be indicative of increased numbers of in-
compatible transplants at a small number of specialty re-
ferral centers, or wider dissemination of these protocols
(13). To examine this, the cumulative distributions in LD
transplants of ABOi and PRA ≥ 80%, over time, are shown
in Figure 25.
In 1999–2000, 244 centers performed at least one LD
transplant, 83 performed at least one transplant of a re-
cipient with PRA ≥ 80% with a non-HLA-identical donor
and 31 centers transplanted at least one ABOi pair. Over
the ensuing decade, the number of centers performing
LD transplants did not increase (244–242) but the number
performing non-HLA-identical PRA ≥ 80% (83–126) and
ABOi (31–50) increased significantly. Furthermore, there
has been increased dissemination of these techniques,
with fewer high-volume centers and broad adoption (as
indicated by a flatter slope of the ABOi and PRA ≥ 80%
curves in 2007–2008 when compared with 1999–2000)
(Figure 25).
Laparoscopic donor nephrectomy: Since the first la-
paroscopic donor nephrectomy reported at Johns Hop-
kins in 1995, use of this operation has become in-
creasingly widespread, with more than 90% of LD
nephrectomies performed laparoscopically in recent years
(Figure 26). Variations in laparoscopic nephrectomy now in-
clude transperitoneal and retroperitoneal approaches, pure
laparoscopic and hand-assisted techniques and, most re-
cently, the single-port procedure (24).
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Table 5: Sensitized and ABO-incompatible transplants, by year of transplant
PRA 80+ ABO incompatible
Year of transplant Total1 MM > 0 MM = 0 Total A2-B A−>B AB–>O B–>A
1999 116 82 31 26 4 7 13 6
2000 138 86 50 31 0 2 25 4
2001 172 125 45 26 4 4 19 3
2002 168 135 32 39 2 6 28 5
2003 250 201 48 52 6 9 36 7
2004 261 220 37 64 1 7 51 6
2005 347 283 60 79 4 15 55 9
2006 340 271 68 95 2 19 68 8
2007 316 272 43 91 0 9 66 16
2008 320 260 53 90 4 23 54 13
Source: SRTR Analysis, August 2009. PRA = panel reactive antibody.
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Figure 25: Facility clustering by
ABO incompatible and PRA 80+
(non-0 mismatch), 1999–2000 ver-
sus 2007–2008.
As with incompatible transplantation above, the broad use
of this operation can be seen not only in numbers but
in distribution by transplant center (Figure 27). For exam-
ple, in 1999–2000, 242 centers performed LD nephrec-
tomies (with nonmissing data on the procedure type), but
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Source: SRTR Analysis, July 2009
Figure 26: Trends in procedure type, 1999–2008.
tomy. Furthermore, there was more clustering of the la-
paroscopic approach when compared with the distribution
of LD transplants in general (Figure 27, left panel). How-
ever, in 2007–2008, while the number of centers that per-
formed LD transplants was still 242, 231 performed at least
one laparoscopic nephrectomy and only 101 performed at
least one open nephrectomy. This is also reflected by clus-
tering, where the open procedure is now more clustered
among a small proportion of transplant centers, while the
distribution of laparoscopic nephrectomy mirrors that of
LD transplantation in general (Figure 27, right panel).
National LD assistance center: In October 2007, HRSA
established the National Living Donor Assistance Center
(NLDAC) to ‘provide reimbursement for travel and sub-
sistence expenses incurred toward living organ donation’.
Donors and recipients with incomes within 300% of the
HHS poverty guidelines, or those with an official statement
of financial hardship from a transplant center representa-
tive, are eligible for up to $6,000 of financial assistance
for travel, lodging and meals for the donor and up to two
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Figure 27: Facility clustering by pro-
cedure type, 1999–2000 versus 2007–
2008.
accompanying persons. As of June 2009, NLDAC had re-
ceived 663 applications, of which 571 were approved. Ap-
proved applications have facilitated 295 completed donor
surgeries; 200 surgeries remain pending and 76 have been
cancelled.
Conclusion
Living donation remains the best strategy to improve ac-
cess to kidney transplantation. LD transplants have the
best outcomes of any kidney transplant, resulting in the
greatest number of life years from transplant. The de-
creasing availability of this resource is particularly alarming,
given the decline in the number of SCD DD kidneys avail-
able. The transplant community should focus on strate-
gies to improve access to living donation for recipients
of all races, ethnicities and socioeconomic status. Through
the adoption of laparoscopic donor nephrectomy, KPD and,
perhaps, ABOi transplant, we hope to reverse the down-
ward trend in LD transplants. It may also be necessary to
consider greater economic support of donors through the
donor assistance program to remove nonclinical barriers to
organ transplantation.
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